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With its hallucinations, delusions, thought disorder,
and cognitive deficits, schizophrenia affects the most
basic human processes of perception, emotion, and
judgment. Evidence increasingly suggests that schizo-
phrenia is a subtle disorder of brain development and
plasticity. Genetic studies are beginning to identify
proteins of candidate genetic risk factors for schizo-
phrenia, including dysbindin, neuregulin 1, DAOA,
COMT, and DISC1, and neurobiological studies of
the normal and variant forms of these genes are
now well justified. We suggest that DISC1 may offer
especially valuable insights. Mechanistic studies of
the properties of these candidate genes and their pro-
tein products should clarify the molecular, cellular,
and systems-level pathogenesis of schizophrenia.
This can help redefine the schizophrenia phenotype
and shed light on the relationship between schizo-
phrenia and other major psychiatric disorders. Under-
standing these basic pathologic processes may yield
novel targets for the development of more effective
treatments.
Introduction
Schizophrenia, affecting about 0.5 to 1.0 percent of the
population worldwide with devastating consequences
for affected individuals and their families, is the seventh
most costly medical illness to our society (Freedman,
2003). The available symptomatic treatment is only par-
tially successful, and therefore the development of ratio-
nal therapeutics, based on an understanding of the etiol-
ogy and pathogenesis of schizophrenia, is imperative.
However, until recently, progress in schizophrenia has
been painfully slow and limited by a number of factors,
including the heterogeneity of the schizophrenia pheno-
type and the lack of clear pathological lesions like those
that have provided reference points in the study of
Alzheimer’s disease (AD), Parkinson’s disease (PD),
and other neurodegenerative disorders (Ross and Marg-
olis, 2005). Investigation into the mechanism of action of
*Correspondence: caross@jhu.eduthe drugs used to treat schizophrenia has not provided
clear understanding of the pathogenesis of the disease.
While schizophrenia is highly heritable (it has a heritabil-
ity score of approximately 0.8), the genetics are complex
and the interpretation of genetic data has proven diffi-
cult. Now, however, advances in phenotypic analysis,
neuroimaging, genetics, and molecular pathology pro-
vide the basis for optimism. Schizophrenia can be un-
derstood, at least in part, as a subtle disorder of brain
development (Arnold et al., 2005; Harrison and Wein-
berger, 2005; Rapoport et al., 2005). Evidence now sup-
ports an etiologic role for mutations or polymorphisms
in a number of genes (Chen et al., 2006; Craddock
et al., 2006; Owen et al., 2005; Riley and Kendler,
2006), as well as obstetrical and premorbid abnormali-
ties of development and cognition. We argue in this
review that a definitive study of the neurobiology of
schizophrenia is now possible.
Lessons from Neurodegenerative Diseases
The success in understanding etiology and pathogene-
sis of neurodegenerative disorders such as AD, PD,
and Huntington’s disease and related polyglutamine
diseases suggests some potential lessons for schizo-
phrenia. First, even for complex diseases, there can be
tremendous benefit from understanding rare familial
variants (Ross and Margolis, 2005). Schizophrenia is
likely to be more complicated than the neurodegenera-
tive disorders, since the search for Mendelian variants
has been less rewarding. But possibly other chromo-
somal translocations (see below), as well as the identifi-
cation ofDISC1, suggests that this approach may yet be
fruitful. Second, identification of more than one causa-
tive gene may help define a pathogenic pathway, and
therapeutic targets, via the interaction of gene products.
For instance, presenilin 1 and presenilin 2 mutations
both cause familial AD through aberrant cleavage of
the APP protein. Similarly, understanding the interac-
tions of gene products mutated in genetic PD is begin-
ning to elucidate the pathogenesis of familial, and po-
tentially sporadic, PD (Smith et al., 2005). Third, with
the identification of the genetic causes of neurodegen-
erative diseases, commonalities among the different
disorders are now emerging, such as the presence of in-
clusion bodies and other deposits of aggregated protein
(Ross and Poirier, 2005). Fourth, mutations that increase
the risk of developing a disease but are not by them-
selves causative can also be illuminating. For instance,
ApoE polymorphisms, which influence the risk for AD,
appear to alter the metabolism of the A-Beta peptide,
providing additional insight into AD pathogenesis. Fi-
nally, genetic changes need not be point mutations,
frame shifts, or deletions. RNA as well as protein can
be neurotoxic (Margolis et al., 2006). Diseases can also
be caused by alterations in the dosage of genes, such
as the duplications and triplications of a-synuclein that
cause familial PD (Singleton et al., 2004). More subtle
alterations in levels of expression may also increase
susceptibility to PD (Singleton et al., 2004) and AD.
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Schizophrenia is increasingly viewed as a subtle disorder
of neurodevelopment. A chromosome 22 microdeletion
syndrome termed Velocardio Facial Syndrome (VCFS) is
associated with schizophrenia. As described below, it
may offer clues to schizophrenia’s pathogenesis.
We suggest that the severe disorders of cortical de-
velopment, grouped together as the lissencephalies,
may also provide clues to the etiology and pathogenesis
of schizophrenia. Lissencephaly involves severe abnor-
malities of the normal ‘‘inside out’’ development of the
cerebral cortex. Neurons migrate from the ventricular
zone toward the pial surface, guided by radial glia, di-
rected in part by secretion of Reelin by Cajal-Retzius
or subpial granular layer cells. Migration of the neuronal
cell body is mediated via microtubule-based transport
organized by the centrosome. First the centrosome
moves up the microtubules, followed by the nucleus
and the cell body (D’Arcangelo, 2006; Hatten, 2002;
Kato and Dobyns, 2003; Olson and Walsh, 2002; Tsai
and Gleeson, 2005).
Reelin is believed to have a key role in directing corti-
cal neuronal migration. Mutations in Reelin are one
cause of lissencephaly. Other major genes whose muta-
tions can cause lissencephaly are Lis1 and doublecortin
(DCX), both of which are involved in regulation of micro-
tubule-based transport. The potential roles of these
molecules in the more subtle abnormalities of neuronal
migration and positioning detected in schizophrenia
and in models of DISC1 mutation are described below.
Furthermore, the example of lissencephaly is another
example, like that of familial AD, of the utility of knowing
several genes, which, when mutated, lead to similar
phenotypes. Also, the N-methyl-D-aspartate (NMDA) re-
ceptor has been shown to stimulate neuronal migration,
so that impaired function of this receptor could contrib-
ute to the developmental phenotype. With mutations in
several genes leading to the same phenotype, it be-
comes possible to identify relationships among their
protein products and ultimately piece together the
framework of a pathogenic pathway.
Schizophrenia Clinical Features and Therapeutics
Schizophrenia is a heterogeneous syndrome without any
single defining symptom or sign and is unidentifiable
with any known diagnostic laboratory tests. The diagno-
sis is applied to individuals with psychotic phenomena
(hallucinations, delusions, and thought disorder) after
other causes of psychosis, such as affective disorder
or delirium, have been excluded. Many individuals with
schizophrenia exhibit negative symptoms, including di-
minished emotional expression and reaction, diminished
participation in interpersonal relationships, diminished
production of speech, and apathy, with loss of energy,
drive, and interests. While less striking than positive
symptoms, negative symptoms may be more impairing
and less responsive to treatment. The symptom profiles
of bipolar disorder (which involves dramatic alterations
of mood, with psychotic phenomena as a frequent ac-
companiment) and schizophrenia frequently overlap.
The success of genetic and neurobiological investiga-
tions of schizophrenia is likely to be dependent on un-
derstanding the heterogeneity of schizophrenia. One
approach has been to divide patients into subtypesbased on their predominant clinical manifestations. For
instance, the 25%–30% of individuals with chronic
schizophrenia who have predominantly negative symp-
toms (Kirkpatrick et al., 2001) have been defined as
having ‘‘deficit’’ schizophrenia. However, other attempts
to subtype schizophrenia in the past have not been very
fruitful, so caution should be exercised. The use of di-
mensionally distinctive features, such as negative symp-
toms or cognitive abnormalities, as quantitative traits
may be more productive.
The onset of schizophrenia most commonly occurs in
the second or third decade of life, though onset age may
vary from childhood to old age. Subtle abnormalities of
cognition, social interaction, motor function, and physi-
cal morphology are frequently observed in individuals
who later develop schizophrenia (Niemi et al., 2003),
which is suggestive of a developmental vulnerability.
Clinical Features: Endophenotypes
An alternative approach to classification of heteroge-
neous disorders is to define endophenotypes (or inter-
mediate phenotypes) (Cannon, 2005; Gottesman and
Gould, 2003). These are heritable, and often quantita-
tive, traits that may not be readily apparent in routine
clinical examinations of affected individuals, yet may
reflect neurobiological features underlying the disease
and may be useful in genetic linkage studies. Ideally, en-
dophenotypes in schizophrenia will reflect abnormali-
ties of specific neural systems under relatively simple
genetic control. Valid endophenotypes will associate
with schizophrenia in population studies, will be present
(though less prominent) in the first degree family mem-
bers of probands with schizophrenia, and will be found
at similar levels in both members of twins discordant
for schizophrenia.
A variety of potential endophenotypes have been as-
sociated with schizophrenia, though none has yet been
confirmed in large, unselected samples of at-risk individ-
uals. For instance, disordered eye movements, which
can be measured using quantitative methods, include
antisaccade performance (associated with frontal-stria-
tal function) (Ettinger et al., 2006) and abnormal smooth
pursuit eye movements, especially the predictive pursuit
component of this function (Hong et al., 2006). Attenu-
ated inhibition of the P50 auditory event-related poten-
tial, a sensory motor gating task, may reflect deficits in
attention and vigilance (Erwin et al., 1998). The P300
event-related potential, a measurement of cortical activ-
ity taken during stimuli discrimination tasks that also
reflects attention and working memory, is attenuated
both in individuals with schizophrenia and, to an inter-
mediate extent, in their relatives (Bramon et al., 2006).
Structural and functional neuroanatomic deficits, as re-
vealed by imaging studies, have also been proposed as
endophenotypes.
Clinical Features: Neuropsychology
While the psychotic phenomena of schizophrenia are
striking, more subtle cognitive problems are increas-
ingly recognized as central to the disease. Impairments
in cognition include attention, working memory, learn-
ing, verbal fluency, motor speed, and executive func-
tions. While positive and negative symptoms of schizo-
phrenia can fluctuate, cognitive deficits remain relatively
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141Figure 1. Structural Abnormalities Identified
by MRI Scan in Schizophrenia
Location of voxel-based morphometry find-
ings of significant volume deficits in the me-
dial temporal lobe (including the amygdala
and hippocampus) in patients with schizo-
phrenia. The top images are left and right
3D images, respectively; the bottom left im-
age is a coronal view, and the bottom right
image is an axial view. The color scale depicts
the stringency of the statistics used in the
studies. From Honea et al. (2005), with per-
mission of the publisher.stable, and are already apparent in first-episode pa-
tients who have never received antipsychotic medicines
(Harvey et al., 2003). Cognitive deficits are found in the
biological relatives of subjects with schizophrenia (Snitz
et al., 2006), suggesting that aspects of cognition im-
paired in schizophrenia may be under specific genetic
control, and therefore, serve as informative endopheno-
types in the genetic analysis of schizophrenia. Cognitive
dysfunction has been recognized as a core feature of
schizophrenia (Antonova et al., 2004; Gold, 2004), lead-
ing to impairment of skills and diminished functional
capacity (Bowie and Harvey, 2005).
The National Institute of Mental Health (NIMH)-spon-
sored Measurement and Treatment Research to Im-
prove Cognition in Schizophrenia (MATRICS) initiative
(Nuechterlein et al., 2004) is developing a consensus
around a cognitive battery for use in clinical trials in
schizophrenia. It incorporates seven cognitive domains,
including Speed of Processing, Attention/Vigilance,
Working Memory, Verbal Learning and Memory, Visual
Learning and Memory, Reasoning and Problem Solving,
and Social Cognition.
Working memory dysfunction in schizophrenia has
been linked to dysfunction of the dorsolateral prefrontal
cortex (DLPFC) (Goldman-Rakic, 1999). Even schizo-
phrenia patients with good performance on working
memory tasks are inefficient in their use of prefrontal net-
works. Behavioral strategies for cognitive improvement
can be effective in improving neurocognitive deficits.
Clinical Features: Neuroimaging
Recent advances in imaging technology (such as fMRI
and diffusion tensor imaging, or DTI) have enabled in-
vestigators to move beyond measures of isolated re-
gional abnormalities and instead begin the exploration
of the function and structure of the interconnected
neural networks that are implicated in schizophrenia.
The most consistent structural abnormalities found in
schizophrenia include lateral and third ventricular en-
largement; medial temporal lobe (hippocampal forma-
tion, subiculum, parahippocampal gyrus) volume reduc-tions; and superior temporal gyrus (STG) volume
reductions, particularly on the left (Figure 1). There is
also moderate evidence for frontal lobe volume reduc-
tion, particularly of prefrontal and orbitofrontal regions,
and parietal lobe abnormalities. Enlarged cavum septi
pellucidi, basal ganglia abnormalities, corpus callosum
abnormalities, thalamus abnormalities, and cerebellar
abnormalities are also evident (Antonova et al., 2004;
Honea et al., 2005; Niznikiewicz et al., 2003). Some, but
not all, studies have suggested that structural changes
may be progressive (Rapoport et al., 2005).
Structural neuroimaging suggests that abnormal pro-
cesses in schizophrenia occur at different stages of neu-
rodevelopment. There is evidence for an early neurode-
velopmental lesion (pre- or perinatal) that may render
the brain vulnerable to anomalous late neurodevelop-
mental processes (particularly postpubertal); these
anomalous late neurodevelopmental processes may in-
teract with other environmental factors associated with
the onset of psychosis (e.g., stress, substance use),
which together have neuroprogressive sequelae that
may be neurodegenerative (Pantelis et al., 2005; Rapo-
port et al., 2005). Abnormal brain structure may be
detectible via MRI prior to the onset of psychotic symp-
toms (Lymer et al., 2006).
Studies of executive function and memory using fMRI
have reported abnormalities of the DLPFC, medial tem-
poral lobe, hippocampus, parahippocampal gyrus, an-
terior cingulate, medial frontal and posterior parietal
cortex, striatum, thalamus, and cerebellum (Niznikie-
wicz et al., 2003). Recent fMRI studies have focused
on the integration of genetic and neuroimaging data
(for review see Turner et al., 2006). The fMRI studies sug-
gest that for any given task that is performed poorly by
individuals with schizophrenia, there is a network of
affected brain regions related to the abnormal function,
rather than a single abnormal brain region, raising the
issue of the state of the interconnections between
regions.
DTI, a technique based on the direction of water diffu-
sion, can probe white matter abnormalities in the brain.
Neuron
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velopment, have raised the possibility of white matter
disorganization in brain regions such as prefrontal and
temporal white matter, corpus callosum, and uncinate
fasciculus (Kanaan et al., 2005; Kubicki et al., 2005).
More systematic and detailed confirmatory studies are
now necessary. A potentially powerful approach may
be to combine fMRI and DTI to probe potential brain
circuit abnormalities in schizophrenia.
Neuropathology
Neuropathological investigations of schizophrenia (Ar-
nold et al., 1998) have not found any evidence of the
usual features of neurodegenerative diseases, such as
inclusion bodies, dystrophic neuritis, or reactive gliosis.
There is intriguing, though not always consistent, evi-
dence of subtle cytoarchitectural anomalies in entorhi-
nal gray matter (Arnold et al., 1997) and in other cortico-
limbic regions, and an abnormally high frequency of
aberrant neurons in the white matter underlying prefron-
tal cortex (e.g, Akbarian et al., 1996), temporal, and para-
hippocampal regions (Arnold et al., 2005). While these
findings remain open to various interpretations (Arnold
et al., 2005), together they provide suggestive evidence
for subtle abnormalities in neurodevelopment in schizo-
phrenia, such as disordered cortical neuronal migration,
consistent with the observation of subtle behavioral,
neurological, and morphologic abnormalities.
Another line of evidence suggestive of neurodevelop-
ment abnormality derives from findings of a reduction
in the volume of cortical neuropil without comparable
neuronal loss (Selemon et al., 1995; Selemon and Gold-
man-Rakic, 1999). Many (though not all) ultrastructural,
immunohistochemical, and other quantitative neuro-
pathological studies suggest quantitative and qualita-
tive deficits in neuronal processes and synaptic connec-
tivity in schizophrenia (Honer et al., 2000). A summary of
neuronal connections implicated in the pathology of the
neuropil in schizophrenia is shown in Figure 2.
Gene expression array studies have compared the ex-
pression profiles, in a number of different brain regions,
of schizophrenias and controls (Katsel et al., 2005).
These studies have yielded inconsistent results and still
need to overcome the difficulties inherent in the usage of
postmortem brain tissue. Genes related to GABA neuro-
transmission, synaptic transmission, and metabolism
have been implicated, though the significance remains
uncertain. Several studies have identified abnormal
expression of genes related to myelination, suggesting
the possibility of glial and white matter abnormalities,
which could be fundamental to the disease, given the
imaging indications of white matter abnormalities noted
above.
Pharmacology
Treatment for schizophrenia remains far from optimal.
While psychosocial programs and various forms of real-
ity-based therapy are helpful, the mainstays of treat-
ment are medications tautologically termed ‘‘antipsy-
chotics.’’ The antipsychotics, first introduced over 50
years ago with the serendipitous discovery that chloro-
promazine was effective in reducing the ‘‘positive’’
symptoms of schizophrenia, all have as their primary
mechanism of action blockade of dopamine D2 recep-tors (Snyder, 2006). This ‘‘first’’ generation of antipsy-
chotics included chlorpromazine, haloperidol, and per-
phenazine, and, while clearly more effective than
placebo, they had a propensity to cause acute and
chronic neurologic symptoms, including tremor, rigidity,
dystonia, and dyskinesia.
More recently, a ‘‘second’’ generation of antipsy-
chotics, such as clozapine and olanzapine, have been
developed that have reduced risk for these acute and
chronic neurologic side effects, possibly because of
their additional blockade of serotonin 5HT2A receptors.
However, it is now apparent that these newer antipsy-
chotics confer a much greater risk for obesity, hyperlip-
idemia, and type II diabetes. Furthermore, recent head-
to-head comparisons between the older, off-patent
perphenazine and the newer atypical antipsychotics
did not disclose major differences in efficacy or tolera-
bility by patients with schizophrenia (CATIE, 2005).
While the antipsycotics generally reduce positive
symptoms, poor compliance and the lack of impact on
negative and cognitive symptoms mean that most indi-
viduals with schizophrenia remain substantially disabled
and unemployed, and require supervised housing ar-
rangements for the rest of their lives. The one exception
appears to be clozapine, which is significantly more ef-
fective, causes improvement in a subgroup of patients
unresponsive to other antipsychotics, and can reduce
negative symptoms (McEvoy et al., 2006).
Clinical trials (Coyle, 2006; Heresco-Levy et al., 2002;
Lane et al., 2005; Tsai and Gleeson, 2005) with agents
which modulate NMDA receptors, including glycine, D-
Serine, D-cyclosperine, sarcosine, or D-alanine, have
suggested improvement in negative and cognitive
symptoms when these agents are added to either typi-
cal or atypical antipsychotics. However, the doses and
Figure 2. Cortical Circuitry in Schizophrenia
Schematic diagram summarizing disturbances in the connectivity
between the mediodorsal (MD) thalamic nucleus and the dorsal pre-
frontal cortex (PFC) in schizophrenia. From Lewis and Lieberman
(2000).
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als, and larger, more definitive trials may be indicated.
Other agents under investigation to enhance NMDA
receptor function indirectly, thereby treating the nega-
tive and cognitive symptoms unresponsive to antipsy-
chotics, include AMPAkines, which prolong AMPA
receptor open time, positive modulators of the metabo-
tropic mGluR5 receptors, and mGlu2/3 receptor ago-
nists (Moghaddam, 2003).
Pathophysiology
Hypotheses regarding pathophysiology of schizophre-
nia originated from pharmacology (Snyder, 2006). The
‘‘dopamine hypothesis’’ derived, in part, from the identi-
fication of D2 receptor blockade as the mechanism for
the action of antipsychotics, and was supported by the
observation that stimulants acting via dopamine, such
as amphetamines, can cause psychosis in normal indi-
viduals and can exacerbate psychosis in individuals
with schizophrenia. Pharmacological and physiological
studies indicate that dopamine modulates cognitive
function in the prefrontal cortex, a finding of potential
relevance to schizophrenia.
Evidence for a role of glutamate in schizophrenia also
originated from pharmacology (Coyle, 2006). NMDA re-
ceptor antagonists, such as ketamine and phencyclidine
(PCP), can cause psychotic and cognitive abnormalities
reminiscent of schizophrenia. In addition, subjects with
schizophrenia appear to be especially sensitive to the
psychotomimetic effects of these drugs. The extent to
which these effects recapitulate schizophrenic patho-
physiology remains uncertain. As noted above, treat-
ment of schizophrenia with D-Serine, glycine, and sarco-
sine, which modulate NMDA receptors, has therapeutic
benefit, particularly with regard to negative symptoms.
Thus, hypofunction of the NMDA receptor, possibly
on critical GABA interneurons, may contribute to the
pathophysiology of schizophrenia (Coyle, 2006).
The potential role for GABA in the pathogenesis of
schizophrenia derives mostly from neuropathologic
studies (Lewis et al., 2005). A particular subtype of
GABA interneurons, chandelier neurons, have decreased
immunostaining for the GABA transporter (GAT), possibly
related to reduced BDNF signaling or NMDA receptor
hypofunction. Consistent with the inferred reduced
GABAergic neurotransmission, ligand binding and im-
munocytochemical studies have revealed upregulation
of the postsynaptic GABA-A receptors in these sectors.
The extent to which these changes represent primary
pathogenesis has yet to be determined.
Mouse Models of Pathogenesis
Functional hypotheses of schizophrenia can now be ad-
dressed using mouse models, aided by the recognition
that observation of some aspects of the schizophrenia
phenotype and endophenotype do not require the self-
reports of affected individuals (Chen et al., 2006). Behav-
iors that have been used as outcome measures in mice,
with varying resemblance to the clinical features of
schizophrenia, include social interaction, prepulse
inhibition, aggression, and locomotor activity. Mouse
models associated with selected candidate genes are
discussed below.For instance, knock out of the dopamine transporter
or overexpression of D2 dopamine receptors causes be-
havioral abnormalities, and overexpression of the D2
receptor in the forebrain causes cognitive changes rem-
iniscent of those observed in schizophrenia (Kellendonk
et al., 2006). Similarly, mice with alterations in molecules
downstream of dopamine signaling such as DARPP-32
(dopamine and cyclic adenosine monophosphate-regu-
lated phosphoproteins of 32 kDa) have behavioral phe-
notypes that may be relevant to schizophrenia. Targeted
deletion of the calcineurin gene yields abnormal loco-
motion, decreased social interactions, and altered cog-
nition, consistent with evidence of decreased cortical
calcineurin. Caron’s group developed a mutant mouse
line that expressed only 5% of normal levels of the
NMDA receptor subunit NR1 (Mohn et al., 1999). These
mice exhibited hyperactivity that responded to the typi-
cal antipsychotic haloperidol, but they also exhibited
impaired social behaviors and mating that were partially
reversed by the atypical antipsychotic clozapine.
These studies of candidate genes, based on func-
tional hypotheses, provide interesting behavioral and
pathophysiologic information, which is in many cases
relevant to understanding the pharmacology of schizo-
phrenia treatment, and in some cases of potential rele-
vance to disease pathogenesis. However, we believe
that the development of mouse models based on etio-
logic risk factors, such as the genes discussed below,
will ultimately provide the most powerful tools for under-
standing the neurobiology of schizophrenia.
Genetic Etiologies: Genes Identified in Linkage
or Association Studies
Linkage and association studies have now implicated
several loci in the genome that appear likely to harbor
genes conferring risk for schizophrenia (Figure 3, Table
1). Candidate genes identified by a genetic approach
have the advantage over candidate genes chosen based
on pharmacotherapies or pathological studies in that
they are of necessity involved in the disease process,
at least for the populations in which the genetic results
were obtained. It should be kept in mind that schizo-
phrenia genetics are complex, with multiple genes of
modest effect interacting to produce the phenotype.
Relative risk at the loci identified so far range between
1.5 to 2.0, indicating modest effect sizes. Simple muta-
tions with Mendelian inheritance and complete pene-
trance have not yet been found using standard linkage
and association methods, though study of chromo-
somal translocations provides a useful alternative.
Neuregulin 1
Neuregulin 1was identified as a candidate gene via fine-
mapping of a locus on chromosome 8p linked to schizo-
phrenia (Harrison and Law, 2006; Stefansson et al.,
2002). A number of studies have found association with
schizophrenia within the neuregulin 1 region. The neure-
gulin 1 gene is very complex, with at least 25 exons
spread over almost a megabase, with extensive alterna-
tive promoter usage and alternative splicing, resulting
in multiple possible protein products. A region in the 50
end of the gene appears to most consistently associate
with disease. Unfortunately, no functional polymor-
phisms have been identified. Most neuregulin 1 isoforms
Neuron
144Figure 3. Locations of Linkage Findings and Genes
Chromosomal regions with significant linkage to schizophrenia are indicated by vertical blue lines. Chromosomal deletions are shown with
vertical red lines. The red arrows refer to the location of chromosomal abnormalities associated with schizophrenia. The yellow arrows and cir-
cles show the locations of the genes identified by linkage and association. The red arrows circles indicate genes identified via translocations.
Adapted from Owen et al. (2005).are transmembrane proteins, which can undergo pro-
teolytic cleavage to release extracellular fragments,
intracellular fragments, transmembrane receptors, or
membrane-bound signaling proteins.Neuregulin 1 signaling, via ErbB receptors and regula-
tion of both NMDA receptors and postsynaptic density
95 (PSD-95), has been implicated in neuronal differenti-
ation and migration. In addition, a C-terminal fragmentTable 1. Candidate Schizophrenia Susceptibility Genes and the Strength of Evidence in Four Domains
Strength of evidence (0 to 5+)
Association with
schizophrenia Linkage to gene locus Biological plausibility
Altered expression
in schizophrenia
COMT 22q11 ++ ++++ +++ yes, +
DTNBP1 6p22 +++++ ++++ ++ yes, ++
NRG1 8p12-21 +++++ ++++ +++ yes, +
RGS4 1q21-22 +++ +++ ++ yes, ++
GRM3 7q21-22 +++ + ++ no, ++
DISC1 1q42 ++++ ++ ++++ not known
DAOA (G72/G30) 13q32-34 +++ ++ ++ not known
DAAO 12q24 ++ + ++++ not known
PPP3CC 8p21 + ++++ ++++ yes, +
CHRNA7 15q13-14 + ++ +++ yes, +++
PRODH2 22q11 + ++++ ++ no, +
AKT1 14q22-32 + + ++ yes, ++
GAD1 2q31.1 ++ ++ yes, +++
ERBB4 2q34 ++ yes, ++
FEZ1 11q24.2 ++ +++ yes, ++
MUTED 6p24.3 ++++ ++++ +++ yes
MRDS1 (OFCC1) 6p24.3 ++ ++++ + not known
NPAS3 9q34 ++ ++ not known
GRIK4 11q23 ++ + ++ not known
Adapted from Straub and Weinberger (2006).
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145of Neuregulin 1 can translocate to the nucleus and inter-
act with transcription factors to enhance expression of
genes, including PSD-95. The functional role of neure-
gulin 1 in schizophrenia is still uncertain, particularly
since many different alleles and haplotypes have been
implicated. However, recent biochemical experiments
in human postmortem tissue suggest that neuregulin 1
signaling may be enhanced in schizophrenia, leading
to suppression of NMDA receptor function (Hahn et al.,
2006). This would be consistent with the glutamate
hypofunction hypothesis of schizophrenia (see above).
No consistent changes in the expression level of Neure-
gulin 1 itself have been detected in schizophrenia, and,
in the absence of mutations changing protein sequence,
it is unclear how this increased activation would come
about. One possibility is the existence of polymor-
phisms that lead to alternative splice variants that en-
code protein products with enhanced function.
Mouse models with heterozygous deletions of the
transmembrane domain of neuregulin 1 have altered ac-
tivity and prepulse inhibition (Chen et al., 2006). How-
ever, the relation of the deletion in this model to changes
in human schizophrenia is unclear. No coding mutations
have been detected in schizophrenia. The region impli-
cated in schizophrenia by haplotype analysis is up-
stream from the transmembrane domain, and includes
the initial exon of the type II isoform (Falls, 2003), and
mouse models with alterations in this region have not
yet been described.
Dysbindin
Dysbindin (dystrobrevin binding protein I) was identified
as a gene associated with schizophrenia through link-
age to chromosome 6p (Straub et al., 2002). The associ-
ation between this locus and schizophrenia has been
replicated in several subsequent studies. Dysbindin co-
localizes with dystrobrevin in both muscle and brain. It is
widely distributed in brain, and has been detected both
pre- and postsynaptically, including in synaptic termi-
nals in the hippocampus (Benson et al., 2001). The func-
tion of dysbindin in brain is not well understood. It has
been reported to influence glutamate neurotransmission
(Numakawa et al., 2004). Mutations in dysbindin also
cause Hermansky-Pudlak syndrome type 7 (Li et al.,
2003), a complex genetic disorder related to lysosome
biogenesis, which is not known to have a psychiatric
phenotype. A deletion within the homologous gene in
mice accounts for the phenotype known as ‘‘Sandy,’’
with albinism and bleeding disorders.
While the association of dysbindin with schizophrenia
has been fairly well replicated, no protein coding muta-
tions contributing to the risk for schizophrenia have
been identified. Furthermore, many different alleles and
haplotypes have been implicated in different studies
(e.g., Burdick et al., 2006; Gornick et al., 2005). Reduced
levels of expression of dysbindin message or protein
have been found in schizophrenic brains (Bray et al.,
2005), raising the possibility that polymorphisms in dys-
bindin associated with schizophrenia may modulate
dysbindin expression level. In addition, knockdown of
endogenous dysbindin with siRNA resulted in reduction
of glutamate levels in neurons in culture, suggesting a
possible synaptic consequence for reductions in dysbin-
din levels (Numakawa et al., 2004; Talbot et al., 2004) andconnecting dysbindin with the glutamate hypofunction
hypothesis of schizophrenia.
Two studies have independently described an associ-
ation between dysbindin risk haplotypes and high levels
of negative symptoms in schizophrenia (Fanous et al.,
2005; DeRosse et al., 2006), supporting the importance
of careful delineation of different domains of schizophre-
nia symptoms. This finding is consistent with other evi-
dence that dysbindin haplotypes may influence prefron-
tal brain function (Fallgatter et al., 2006). Thus, further
study of dysbindin genotypes in relationship to specific
subtypes of schizophrenia and to cognitive endopheno-
types appears warranted, as does detailed investigation
of the role of dysbindin in glutamate neurotransmission
and other neuronal functions. Further mouse models of
dysbindin alterations would be very valuable.
D Amino Acid Oxidase Activator
The chromosome 13 locus has strong linkage regions to
schizophrenia. Among other genes, this locus contains
G72, now called D amino acid oxidase activator
(DAOA). Several individual replication studies and a
meta-analysis have supported the association of DAOA
with schizophrenia, though as with other loci, the associ-
ated alleles and haplotypes are not identical across stud-
ies, and some variants are located outside of the gene
(Detera-Wadleigh and McMahon, 2006). Functionally,
DAOA activates D amino acid oxidase (DAO). DAO oxi-
dizes D-Serine, which is a coagonist at NMDA glutamate
receptors. Thus, there is some biologic plausibility for
DAOA as a candidate gene, based on the glutamate
hypothesis. DAOA does not have a homolog in mice, so
no knockout model has been made. Further explorations
of this system may be of considerable interest, especially
given the potential efficacy of D-Serine in therapeutic
trials and reports of reduced D-Serine in blood and
CSF in individuals with schizophrenia.
COMT and Chromosome 22 Region
Another linkage region is on chromosome 22 (Harrison
and Weinberger, 2005; Owen et al., 2005). It has been
supported in many, though not all, linkage and associa-
tion studies. In addition, strong genetic association be-
tween schizophrenia and the chromosomal microdele-
tion syndrome VCFS (Mendelian Inheritance in Man,
MIM 192430), which is caused by deletion of approxi-
mately 1.5 to 3 Mb in chromosome 22q11, supplies
strong evidence for a genetic contribution to schizo-
phrenia from this region. Approximately 20% to 30%
of patients with VCFS have schizophrenia or other major
psychiatric disorders with psychosis (Murphy et al.,
1999). Furthermore, patients with schizophrenia have
increased frequency of the microdeletion compared
with the general population (Karayiorgou et al., 1995).
VCFS includes facial dysmorphism and other features,
and presumably is caused by loss of one copy of several
or many genes in this region. The VCSF region includes
at least 27 genes. The Tbx1 gene may account for many
of the physical features of VCSF (Li et al., 2003; Long
et al., 2006). It is expressed in microvasculature in brain.
Inactivating mutations in Tbx1 have been found in one
small family with VCSF or Asberger’s syndrome (Li
et al., 2003), but the relation of this gene to schizophre-
nia is still incompletely explored.
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most attention is catechol-O-methyltransferase (COMT).
The protein product is an enzyme that participates in the
clearance of dopamine from synapses, and thus could
be involved in regulation of neurotransmission related
to schizophrenia (Craddock et al., 2006; Tunbridge
et al., 2006). A functional polymorphism, involving the
presence of either valine or methione at codon 108 (in
the soluble isoform of COMT, equivalent to codon 158
in the membrane-bound isoform of COMT) alters enzyme
activity. The methione allele is less stable and thus has
lower activity, suggesting the hypothesis that individuals
with two copies of the methione allele, or with a deletion
of one copy of COMT, would be expected to have higher
dopamine levels in critical central synapses, perhaps
especially in the prefrontal cortex.
In a seminal study combining genetics of the COMT
valine/methione polymorphism with imaging methods,
the valine allele, which would have lower synaptic dopa-
mine, was reported to confer risk for schizophrenia via
variation in cognitive function in contradiction to the do-
pamine hypothesis, which proposes increased synaptic
dopamine as the risk mechanism (Egan et al., 2001). The
relationship appears to be complicated (Craddock et al.,
2006; Tunbridge et al., 2006), and the association be-
tween COMT alleles and schizophrenia appears to be
less striking than the association between COMT and
cognitive function. For instance, a relationship between
the valine/methione polymorphism and longitudinal
cognitive decline in patients with the 22q11.2 deletion
syndrome has recently been reported, though not yet
replicated (Gothelf et al., 2005). Variation at the COMT
locus may provide the best studied example of the rela-
tionship between variation at a genetic locus and an
endophenotype closely related to schizophrenia.
Other genes in the deletion syndrome region may also
contribute to the risk for schizophrenia. For instance,
genetic variation of the proline dehydrogenase (PRODH)
influences the availability of glutamate, and mutant mice
with a PRODH loss-of-function exhibit some behavioral
abnormalities. A recent report has postulated an interac-
tion between COMT and PRODH (Paterlini et al., 2005).
However, association and follow-up linkage studies
have not been strongly positive. ZDHHC8, also in the
22q deletion region, encodes a zinc finger domain pro-
tein. However, strong evidence in favor of this gene
has not yet emerged (Harrison and Weinberger, 2005;
Owen et al., 2005).
Other Candidate Genes Based on Linkage Studies
Other candidate genes are listed in Table 1 and de-
scribed in recent reviews (e.g. Harrison and Weinberger,
2005; Owen et al., 2005; Straub and Weinberger, 2006).
Genes Disrupted by Chromosomal Translocations
Genes interrupted by chromosomal translocations so
far appear to be very rare causes of schizophrenia. How-
ever, the advantage is that since translocations produce
a definable genetic lesion, it may be possible to deter-
mine the effects of the mutation on the function of the
gene product.
The Neuronal PAS Domain Protein 3 (NPAS3) gene
codes for a transcription factor containing a basic
helix-loop-helix (HLH) PAS domain involved in tran-scriptional regulation.NPAS3was found to be disrupted
by chromosomal translocation in two related individuals
with schizophrenia (Pickard et al., 2005). Since HLH
domain-containing proteins function as dimers, and be-
cause the translocation could produce a truncated pro-
tein without the transcriptional activation domains, the
truncation might act via a dominant-negative mecha-
nism. Since the family is so small, it is premature to con-
clude that there is a relationship between this gene and
schizophrenia. However, deletions of NPAS transcrip-
tion factors in mice cause behavioral phenotypes and
altered hippocampal neurogenesis (Pieper et al., 2005),
providing additional support for a role of NPAS in
schizophrenia.
A translocation throughGRIK4, which codes for one of
the glutamate kainaite receptors, has also been detected
in an individual with schizophrenia (Pickard et al., 2006).
Subsequent case control studies suggested an associa-
tion of a haplotype within this gene to schizophrenia. A
translocation through PDE4B, as discussed below, has
also been detected in a small family with schizophrenia.
DISC1: Interrupted by a Chromosome
1,11 Translocation
DISC1, in our view, is emerging as the best supported
candidate gene for schizophrenia (Hennah et al., 2006;
Ishizuka et al., 2006; Porteous and Millar, 2006), with a
great potential for future research. DISC1 was identified
via a balanced (1:11) chromosomal translocation, segre-
gating with schizophrenia, bipolar disorder, and other
major mental illness in a large pedigree in Scotland,
with LOD scores of 7 using a broad phenotype. The
translocation is between exons 8 and 9 of the DISC1
gene on chromosome 1. No genes have been found at
the chromosome 11 site.
The translocation has not been found in any other
families. Another small family (Sachs et al., 2005), iden-
tified via a proband with schizophrenia, has a four-
base deletion resulting in a frame shift and predicted
C-terminal truncation of the DISC1 protein. However,
the family is too small to clearly demonstrate segrega-
tion with disease, and the deletion has also been found
in two presumably unaffected blood donors (Green
et al., 2006).
A locus on chromosome 1 within the DISC1 gene was
linked to schizophrenia in a Finnish population (Ekelund
et al., 2001), and the DISC1 locus has emerged as a
potential risk factor for both schizophrenia and affective
disorder in different populations (Craddock et al., 2005;
Hennah et al., 2006; Millar et al., 2003; Thomson et al.,
2005; Porteous and Millar, 2006).
Study of the original Scottish phenotype suggested
two distinctive features of the clinical phenotype. First,
affected individuals have either schizophrenia or affec-
tive disorder. Consistent with this, recent linkage studies
have implicated theDISC1 locus, especially for schizoaf-
fective disorder (Hamshere et al., 2005). Second, re-
duced P300 amplitude and latency, an endophenotype,
was associated with the translocation in both affected
and unaffected translocation carriers (Blackwood et al.,
2001). More recent imaging and neuropsychological
studies have suggested that DISC1 haplotypes, includ-
ing a putative functional polymorphism (S704C), are as-
sociated with altered hippocampal function, altered
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in individuals with and without schizophrenia or affective
disorder (Figure 4), consistent with an influence ofDISC1
on cognitive endophenotypes (Callicott et al., 2005; Can-
non et al., 2005; Porteous et al., 2006).
Variation at the DISC1 locus, via a deletion in exon 6,
may also contribute to phenotypes in mouse substrain
129. The effects of this have not been conclusively
demonstrated, but it appears to abrogate expression.
On transfer of theDISC1 deletion allele to the BL/6 back-
ground, the deletion mice, but not littermate controls,
have selective impairment in working memory (Koike
et al., 2006).
The molecular mechanism of the DISC1 translocation
mutation is uncertain. Most of the evidence points to
loss-of-function effects, but the exact mechanism is
controversial. Loss of function could result from loss of
expression, and thus haploinsufficiency. Alternatively,
it is conceivable that a truncated mutant protein is pro-
Figure 4. Influence of DISC1 Polymorphisms on Functional Brain
Activation
BOLD fMRI and SNP10 (Ser704Cys). DISC1 SNP10 affects hippo-
campal formation activation during working memory tasks in healthy
subjects. For the N-back task, Healthy Ser homozygotes (n = 18)
showed an apparent atypical increase in HF activation, indicated
as yellow-red signal, during the N-back working memory task rela-
tive to Cys carriers (n = 24). From Calicott et al. (2005), with permis-
sion of the publisher.duced. No mutant protein expression was detected in
lymphoblasts from the patients with the Scottish translo-
cation (Millar et al., 2005), though techniques might not
have been sensitive enough to identify low levels of ex-
pression, and expression of transcripts from the mutant
allele could be detected. Biochemical studies have indi-
cated that DISC1 protein has a self interaction domain
and likely functions as a dimer. DISC1 protein with a C-
terminal truncation, corresponding to the protein that
would be produced from the translocation allele, dis-
rupts the normal function and cellular localization of the
full-length protein (Kamiya et al., 2005), suggesting the
possibility of a dominant-negative mechanism. Future
mouse model studies may resolve some of these issues
in vivo. Whether via haploinsufficiency or dominant-neg-
ative interactions, loss-of-function mechanisms imply
that understanding the normal function of DISC1 will be
critical for understanding DISC1-related disease.
DISC1 appears to have roles in both brain develop-
ment and adult neuronal functioning. Developmental
roles include regulation of neuronal migration, neurite
outgrowth, and neuronal maturation. Roles in the adult
appear to include modulation of cytoskeletal function,
synaptic transmission, and plasticity. The expression
of DISC1 is increased during neuronal development,
with peaks at E13.5 during late fetal development and
at P35 in early postnatal periods (Schurov et al., 2004).
Expression continues into adulthood, with the highest
expression in hippocampus, olfactory bulb, lateral sep-
tum, cerebral cortex, and hypothalamus and other
brainstem regions (Austin et al., 2003). DISC1 protein
can be detected in many regions within cortical neurons,
including presynaptic and postsynaptic locations (Kirk-
patrick et al., 2001).
Studies of the protein interaction partners of DISC1,
and the cell biology of these interactions, have greatly il-
luminated DISC1 functions and provided strong support
for roles of DISC1 in brain development and adult neuro-
nal function. Table 2 shows some of the protein interac-
tion partners of DISC1 and their potential cellular roles.
As indicated in Figure 5, the molecular and cellular in-
teractions of DISC1 are critical for normal neuronal de-
velopment and in the adult are implicated in normal neu-
ronal signal transduction and plasticity.
DISC1 interacts with several proteins which them-
selves are implicated in neuropsychiatric diseases. ForTable 2. DISC1 Interactors
DISC1 interactor Interactor function DISC1 binding site Reference
NudEL neuronal migration 727–854 Brandon et al., 2004; Morris et al., 2003;
Ozeki et al., 2003
Lis1 neuronal migration 727–854 Brandon et al., 2004
PDE4B cAMP hydrolysis 219-283 Millar et al., 2005
Citron synaptic function 347–600 Ozeki et al., 2003
a-tubulin cytoskeleton 181–157 Brandon et al., 2004
ATF4/5 transcription factors 598–854 Morris et al., 2003
DISC1 403–504 Kamiya et al., 2005
FEZ1 neurite extension 446–633 Miyoshi et al., 2004
Kendrin centrosome, microtubule 446–633 Miyoshi et al., 2004
eIF3 translation initiation factor 2–231 Ogawa et al., 2005
MAP1A microtubule associated 1–292 Morris et al., 2003
MIPT3 microtubule associated 293–696 Morris et al., 2003
Adapted from Porteous et al. (2006).
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(A) In the developing neuron, DISC1 is part of a complex with NudEL and Lis1, interacting with the dynein/dynactin motor complex, which is in-
volved with microtubule transport and organization of microtubules at the centrosome. This complex is critical for nucleokinesis, and thus, cor-
tical neuronal migration, and is downstream from Reelin signaling via Dab1. DISC1 also has a key role in neurite outgrowth and organization via its
interaction with FEZ1 and actin stress fibers.
(B) In the adult neuron, DISC1 continues to have a role in microtubule-based transport. DISC1 also interacts with Citron, and thus presumably
has functions in postsynaptic responses. DISC1 presumably can modulate neurotransmission (and potentially neuroplasticity) by regulating the
ability of PDE4B to hydrolyze cAMP, a role which may be localized in part to mitochondrial outer membranes. In the nucleus, DISC1 interacts with
transcription factors to modulate stress-induced transcriptional regulation.example, DISC1 interacts with NudEL. Its close homolog
NudE may be genetically related to schizophrenia (Hen-
nah et al., 2006). NudEL is part of a protein complex with
Lis1, downstream of Reelin signaling (Brandon et al.,
2004). As noted above, mutations of Lis1 cause lissence-
phaly, and the presence of DISC1 in the same complex
as Lis1 is consistent with the idea that schizophrenia,
as a relatively mild disorder of cortical development, is
pathophysiologically related to more severe disorders
of cortical development. Reelin mutations also cause lis-
sencephaly. The interaction between DISC1 and both
NudEL and Lis1 would be disrupted by truncated protein
expressed from the putative message produced by the
chromosomal translocation. Finally, DISC1 interacts
with PDE4B, which is itself interrupted by balanced chro-
mosomal translocation in two individuals with schizo-
phrenia or chronic psychiatric illness (Millar et al., 2005).
These interactions are relevant for the cellular func-
tions of DISC1. DISC1 is part of a protein complex in-
cluding, in addition to Lis1 and NudEL, dynein and dy-
nactin, which is critical for neuronal migration (Hatten,
2002; Olson and Walsh, 2002; Tsai and Gleeson, 2005).
Neuronal migration in the cerebral cortex involves
movement along radial glial toward Cajal-Retzius cells
and subpial granular layer cells, which secrete Reelin.
Migration is driven by nucleokinesis, for which microtu-bule-based transport is critical. The DISC1 protein com-
plex appears to have several important functions in this
process. It appears to be critical for assembly of the cen-
trosome and the organization of the cellular microtubule
network. The nucleus is moved by microtubule-based
transport toward the centrosome, and neurites extend
distally from the centrosome, which is also based in
part on microtubule-based transport. Cell biological
studies in the Sawa laboratory indicate that DISC1 is
important for maintaining a protein complex at the
centrosome that is critical for these functions (Kamiya
et al., 2005).
DISC1 also modulates neurite outgrowth (Miyoshi
et al., 2003) (Ozeki et al., 2003). Either loss of normal
DISC1 function or expression of the mutant allele
caused abnormal neurite outgrowth in PC12 cells and
cortical neurons. Furthermore, elegant in vivo studies
in the Nakajima laboratory using in utero electroporation
found delayed migration of cortical neurons expressing
DISC1 siRNA or mutant truncated DISC1. In the adult
cortex, affected neurons continued to have subtle dis-
turbances of neurite orientation (Kamiya et al., 2005).
In addition to microtubules, the actin cytoskeleton is
important for neuronal migration and neurite outgrowth.
DISC1 associates with FEZ1, an actin binding protein
that may have a critical role in anchoring microtubules
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to involve the DISC1/FEZ1 complex (Miyoshi et al.,
2003). DISC1 also interacts with several transcription
factors, including ATF4 and ATF5, suggesting that
DISC1 mutations could potentially alter gene transcrip-
tion (Morris et al., 2003). DISC1 also binds to Citron, a
postsynaptic protein that interacts with PSD-95, sug-
gesting a role for DISC1 in the regulation of synaptic
function and synaptic plasticity.
Finally, as noted above, DISC1 has recently been
shown to interact with PDE4B, with functional conse-
quences for cAMP signaling. Release of PDE4B by
DISC1 activates PDE4B, causing conversion of cAMP
to adenosine monophosphate. cAMP is critical for regu-
lation of protein kinase A, which in turn has many func-
tions in neuronal signaling and plasticity in the cell. Fur-
thermore, PDE4B is a target of the antidepressant
Rolipram, consistent with the postulated involvement
of DISC1 in affective disorder as well as schizophrenia.
Etiology: Environmental Interactions
Environmental and genetic etiologies are both important
in psychiatry (Caspi and Moffitt, 2006) and are believed to
interact in most cases of schizophrenia. Recent immuno-
logic, epidemiologic, and neuropsychiatric studies sug-
gest infectious etiologies of several major neuropsychi-
atric diseases (Yolken et al., 2000). Infections that have
been associated with schizophrenia include rubella, in-
fluenza, Herpes Simplex Virus-1 and -2, cytomegalovi-
rus, poliovirus, and Toxoplasma gondii (Brown and Sus-
ser, 2002). Patterson (2002) has developed evidence that
it is not the virus itself that adversely affects fetal brain
development, but rather the cytokine response mounted
by the infected mother. Infections during pregnancy can
affect brain development by releasing stress hormones,
producing hypoxia, hyperthermia, or malnutrition, or by
triggering proinflammatory cytokine responses of the
mother, the placenta, or the fetus (Gilmore and Jarskog,
1997; Verdoux, 2004). The effects of infection in the peri-
natal and postnatal period can differ. There can be sub-
stantial individual difference in the response to infectious
agents. Among other environmental insults implicated
as risk factors for schizophrenia are obstetric complica-
tions, including premature birth, low birth weight, pre-
eclampsia, rhesus incompatibility, resuscitation at birth,
emergency Cesarean delivery, and prenatal nutritional
deficiency (Cannon et al., 2002; Kyle and Pichard, 2006;
St Clair et al., 2005).
Conclusions and Possibilities for Future Research
In conclusion, we now believe that the molecular genet-
ics of schizophrenia are sufficiently advanced such that
etiology-based studies of the neurobiology of schizo-
phrenia are both justified and feasible. The field is still
in its infancy, and we must struggle to integrate our rudi-
mentary knowledge of schizophrenia genetics with our
scarcely better developed understanding of normal hu-
man brain function. Additional genetic studies are indis-
pensable in this effort, and will now be facilitated by
genome-wide methods for study of association and
methods to systematically investigate variations in ge-
nomic copy number. Epigenetic modification, such as
methylation, may also prove relevant (Abdolmalekyet al., 2005). Mouse models will make it possible to
test pathogenic hypotheses.
How to address the nature and contribution of environ-
mental factors is more uncertain. One possibility may be
to introduce proposed environmental factors, such as
viral infections, to mouse models of identified mutations
in genes such as DISC1 or NPAS3.
The mouse models generated to date have been
based on the study of Mendelian disorders (Chen
et al., 2006). The more subtle etiologies of schizophrenia
and other psychiatric disorders may make more com-
plex genetic models important. For instance, it may be
important to generate models with splicing alterations
in neuregulin 1 or with amino acid polymorphisms in
COMT or DISC1. In addition, it may be important to
use inducible or other conditional systems in order to
mimic the effect of activation of the genetic lesion in
particular tissues at particular times.
In addition to mouse models, genetic models in other
organisms may be very useful. Unlike in neurodegener-
ative diseases, it may be difficult to use Drosophila or
other invertebrates as models for the complexities of
human psychiatric disorders. For understanding alter-
ations of cortical development, zebrafish, in which de-
velopment can be directly visualized, may prove
suitable. Other species with more complex social be-
haviors and more complex cognition may ultimately be
necessary. Perhaps genetically modified primates may
become an important source of models. However, hu-
man patients must remain the gold standard. Studies
of genetics and clinical and imaging phenotypes can in-
creasingly be integrated. Future imaging studies may be
able to combine fMRI with DTI to trace functionally iden-
tified circuits.
We propose that study of DISC1 may offer unique op-
portunities for inroads into understanding the biology of
schizophrenia. DISC1 appears to act as a scaffold for
protein interactions, and some of these interacting pro-
teins have altered expression in schizophrenia (Lipska
et al., 2006). These interactors will be helpful for under-
standing pathogenesis, and can themselves serve as
potential candidate genes to test for mutations. Thus,
a neurogenetic approach based on candidate genes
(Ross and Pearlson, 1996) may now become possible.
The DISC1 interacting protein Lis1 is related to lissence-
phaly, highlighting the idea that schizophrenia, as a
subtle disorder of cerebral cortical development, is
related to more severe disorders of cerebral cortical
development.
Study of the different genetic etiologies of schizophre-
nia will also improve understanding of the schizophrenia
phenotype, and also understanding of affective disorder
and potentially other related major psychiatric illnesses,
just as study of the different genes causing lissence-
phaly has allowed a more careful classification of the
phenotypes of lissencephaly (Kato and Dobyns, 2003).
Some of the genes, such as dysbindin, appear to be
related more specifically to schizophrenia, perhaps es-
pecially deficit schizophrenia, while others such as
DISC1 and neuregulin 1 can relate to both schizophrenia
and affective disorder.
The genes associated with schizophrenia may have
a spectrum of different pathogenic effects, altering neu-
ronal development, neuronal plasticity, and signal
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150Figure 6. Hypothetical Genotype-Phenotype
Relationships via Neurobiological Processes
Based on the very incomplete knowledge
available at present, we hypothesize that ge-
netic vulnerabilities associated more closely
with schizophrenia, and especially deficit
schizophrenia, will involve developmental
pathogenesis, while genes associated with
affective phenotypes will involve pathophysi-
ology more closely linked to neuromodula-
tion. Intermediate phenotypes may involve
plasticity.DISC1 (and neuregulin 1) mutations
may involve a range of phenotypes, and the
molecular interactions, as shown in Figure 5,
could potentially impact a range of cellular
effects. This scheme is undoubtedly a great
oversimplification. The details of the geno-
type-phenotype relationships will have to be
modified as more studies are done. Since
the genetics are complex, several different
genetic vulnerabilities act together with envi-
ronmental factors to cause the phenotype,
except in the case of theDISC1 translocation,
which may be sufficient on its own.transduction. While undoubtedly a great oversimplifica-
tion, it may be of heuristic value to postulate that varia-
tions in particular genes can affect particular neurobio-
logical processes (Figure 6), in turn causing specific
phenotypes. For instance, effects on neurodevelopment
may be more closely associated with schizophrenia,
while effects on signal transduction may be more likely
to cause affective disorder. We suggest that DISC1
may serve as a kind of Rosetta Stone for schizophrenia
research, helping to connect disparate domains. Testing
these broader hypotheses will require integration of re-
search in biochemistry and cell biology, mouse genet-
ics, neuroimaging, and human genotype-phenotype
correlations. These studies may allow us to reconceptu-
alize our definitions of the psychiatric disorders, includ-
ing schizophrenia, based on a better understanding of
etiology and pathogenesis.
Ultimately, neurobiological study of schizophrenia, a
remarkable disorder of brain function, may help illumi-
nate the nature of normal thought, perception, and emo-
tion. Thus, understanding of this most human disorder
may help us better understand human nature itself.
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